Necessary for seizure forecasting outcome metrics: Seizure frequency and benchmark modelChi‐Yuan Chang, Daniel M. Goldenholz, Rosalind W. Picard et al.|Epilepsy Research|2024Cited by 9
A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)James R. Berenson, Robert Vescio, Jennifer To et al.|Blood|2019Cited by 2
Necessary for seizure forecasting outcome metrics: seizure frequency and benchmark modelChi‐Yuan Chang, Daniel M. Goldenholz, Boyu Zhang et al.|medRxiv|2024Cited by 1